Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab Efficacy and Safety in Primary Hypercholesterolemia (ODYSSEY CHOICE II)
NCT02023879Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Dec 2013; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02023879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023879.